FDA announces recall of infusion pumps after thousands of complaints, 1 death

InfuTronix has recalled its Halo Ambulatory Infusion System and several Nimbus pumps after 3,698 complaints and one death, attributed to device failures. Due to a serious risk of medication overdoses and patient dehydration, the U.S. Food and Drug Administration (FDA) has identified this as a Class I recall, the most serious type.

The infusion systems are used in hospitals and healthcare facilities, but are often also used at-home for patients to distribute their own pain medication. Malfunctions in the systems—ranging from battery failures to line blockages—can cause serious adverse health events, including seizures and death.

InfuTronix sent customers an Urgent Medical Device Removal letter in February, recommending use of the recalled systems cease immediately as part of their larger removal from the market.

All recalled devices will no longer be available or supported after June 20, 2024.

What is being recalled?

A total of 52,328 systems released between February 27, 2015 and February 29, 2024 are subject to the urgent recall. The specific product codes for affected devices can be found by clicking the links below:

These infusion pumps and systems are used to administer medications subcutaneously, intradermally, intrathecally and intravenously. In its notice, the FDA warns use of the above products “may lead to serious injury or death.”

Next Steps

Any provider or patient in possession of any of the recalled infusion systems is being instructed to contact InfuTronix at Customerservice@intuvie.com to initiate a return.

Providers are being asked to seek alternatives for patients immediately, as soon as a safe system can be acquired for their patients.

The full FDA recall notice can be found here.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”